Related Experiment Video
Updated: Aug 14, 2026
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Influence of noradrenaline denervation on MPTP-induced deficits in mice
1Department of Psychology, University of Göteborg, Göteborg, Sweden. Trevor.Archer@psy.gu.se
Abstract:
C57/BL6 mice were administered either DSP4 (50 mg/kg, s.c., 30 min after injection of zimeldine, 20 mg/kg, s.c.) or vehicle (saline) at 63 days of age. Three weeks later, one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered MPTP (2 x 40 mg/kg, s.c., 24 hours between injections; the High dose groups), one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered MPTP (2 x 20 mg/kg, s.c., 24 hours between injections; the Low dose groups), and one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered vehicle. Three weeks later, all six groups were tested in motor activity test chambers, followed by injections of L-Dopa (20 mg/kg, s.c.), and then tested over a further 360 min in the activity test chambers. It was found that pretreatment with the selective NA neurotoxin, DSP4, deteriorated markedly the dose-dependent motor activity deficits observed in the vehicle pretreated MPTP treated mice. These 'ultra-deficits' in the spontaneous motor behaviour of MPTP-treated mice were observed over all three parameters: locomotion, rearing and total activity, and were restricted to the 1(st) and 2(nd) 20-min periods. Administration of L-Dopa (20 mg/kg) following the 60-min testing of spontaneous behaviour restored the motor activity of Vehicle + MPTP treated mice (neither the Vehicle + MPTP-Low nor the Vehicle + MPTP-High groups differed from the Vehicle-Vehicle group, here) but failed to do so in the DSP4 pretreated mice. Here, a dose-dependent deficit of L-Dopa-induced motor activity (over all three parameters) was obtained thereby offering further evidence of an 'ultra-deficit' of function due to previous denervation of the NA terminals. The present findings support the notion that severe damage to the locus coeruleus noradrenergic system, through systemic DSP4, disrupts the facilitatory influence on the nigrostriatal DA system, and interferes with the ability of the nigrostriatal pathway to compensate for or recover from marked injury, MPTP treatment.
Insights
DSP4 pretreatment worsens MPTP-induced motor deficits in mice, impairing L-Dopa
Area of Science:
- Neuroscience
- Neuropharmacology
- Parkinson's Disease Research
Background:
- The nigrostriatal dopamine (DA) system is crucial for motor control.
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin used to model Parkinson's disease.
- The noradrenergic (NA) system, particularly the locus coeruleus, may influence nigrostriatal DA function.
Purpose of the Study:
- To investigate the effect of noradrenergic neurotoxin DSP4 on MPTP-induced motor deficits.
- To determine if noradrenergic system damage impacts the efficacy of L-Dopa treatment in an MPTP mouse model.
Main Methods:
- C57/BL6 mice were pretreated with DSP4 or vehicle.
- Mice received MPTP (high or low dose) or vehicle.
- Motor activity was assessed before and after L-Dopa administration.
Main Results:
- DSP4 pretreatment significantly exacerbated MPTP-induced motor activity deficits (locomotion, rearing, total activity).
- L-Dopa effectively restored motor activity in MPTP-treated mice without DSP4 pretreatment.
- L-Dopa failed to restore motor activity in DSP4-pretreated mice, indicating a dose-dependent deficit.
Conclusions:
- Severe damage to the locus coeruleus noradrenergic system disrupts the nigrostriatal DA system's function.
- Noradrenergic denervation impairs the nigrostriatal pathway's ability to compensate for or recover from MPTP-induced injury.
- This highlights the interaction between noradrenergic and dopaminergic systems in motor control and Parkinson's disease pathogenesis.
